13F Holdings
中文EN

SGRY Surgery Partners, Inc.

Services-General Medical & Surgical Hospitals, NEC · Nasdaq · SEC CIK 1638833 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.2%
TTM net income YoY49.2%
TTM EPS YoY50.7%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin10.8%
Net margin-2.6%
FCF margin6.0%
EBITDA margin16.1%

Returns

ROE-5.1%
ROA-1.2%
ROIC (approx.)6.1%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets53.8%
Debt / equity1.84x
Current ratio2.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-3.19x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue2.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.31B$3.11B$2.74B$2.54B$2.23B
SG&A expense$118.20M$138.70M$120.90M$102.20M$104.00M
Operating income$389.50M$348.80M$328.00M$345.20M$302.20M
Pretax income$116.90M$147.10M$135.00M$110.30M$81.20M
Income tax$18.00M$134.60M-$300,000$23.30M$10.50M
Net income-$77.90M-$168.10M-$11.90M-$54.60M-$70.90M
EBITDA$565.50M$501.40M$446.10M$460.00M$401.00M
EPS (basic)-0.61-1.33-0.09-0.59-1.12
EPS (diluted)-0.61-1.33-0.09-0.59-1.12
Weighted avg. shares (diluted)127.21M126.12M125.61M91.95M72.43M
Balance sheet
Cash & equivalents$239.90M$269.50M$195.90M$282.90M$389.90M
Receivables$602.20M$579.10M$496.40M$456.30M$430.20M
Inventory$96.60M$88.40M$75.20M$71.40M$61.10M
Current assets$1.15B$1.12B$895.00M$921.00M$946.10M
PP&E, net$1.15B$1.09B$968.70M$876.60M$629.70M
Goodwill$5.19B$5.07B$4.33B$4.14B$3.91B
Intangibles$41.00M$45.70M$54.80M$42.30M$43.70M
Total assets$8.12B$7.89B$6.88B$6.68B$6.12B
Current liabilities$615.50M$624.40M$523.00M$493.40M$536.80M
Short-term debt$99.30M$101.40M$73.30M$62.80M$60.40M
Long-term debt$3.60B$3.27B$2.70B$2.56B$2.88B
Total debt$3.70B$3.37B$2.78B$2.62B$2.94B
Total liabilities$4.59B$4.25B$3.51B$3.40B$3.82B
Shareholders' equity$1.71B$1.79B$1.99B$2.00B$1.09B
Net debt$3.46B$3.10B$2.58B$2.34B$2.55B
Shares outstanding129.32M127.11M126.59M125.96M89.33M
Cash flow statement
Operating cash flow$274.30M$300.10M$293.80M$158.80M$87.10M
Capital expenditure$78.70M$90.40M$88.80M$80.60M$57.60M
Free cash flow$195.60M$209.70M$205.00M$78.20M$29.50M
Investing cash flow-$246.60M-$488.50M-$225.60M-$307.90M-$331.70M
Financing cash flow-$57.30M$262.00M-$155.20M$42.10M$316.30M
Depreciation & amortization$176.00M$152.60M$118.10M$114.80M$98.80M
Stock-based compensation$14.80M$33.30M$17.70M$18.40M$17.40M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.